HEK293 human embryonic kidney cell line transfected with either (A) human CEACAM-5/CD66e or (B) humanCEACAM-8/CD66b and eGFP was stained with Mouse Anti-Human CEACAM‑5/CD66e Monoclonal Antibody (Catalog # MAB41281) ...read more
CEACAM‑5/CD66e was detected in immersion fixed paraffin-embedded sections of human colon using Mouse Anti-Human CEACAM‑5/CD66e Monoclonal Antibody (Catalog # MAB41281) at 10 µg/mL for 1 hour at room ...read more
CEACAM-5, also known as CEA and CD66e, belongs to the large family of CEACAM and pregnancy specific glycoproteins. CEACAM molecules are either transmembrane or GPI-linked, and are differentially expressed between species (1, 2). Orthologs of human CEACAM‑5 have not been described in other species. CEACAM-5, which is expressed primarily by epithelial cells, consists of an N-terminal Ig-like V-set domain followed by six Ig-like C2-set domains and a GPI anchor (2‑4). CEACAM-5 is synthesized as a 180 kDa, variably glycosylated molecule of which approximately 60% is carbohydrate (5). CEACAM-5 functions as a calcium‑independent adhesion molecule through homophilic and heterophilic interactions with CEACAM-1 (6‑8). CEACAM-5 is restricted to the apical face of intestinal epithelial cells in the adult but is more diffuse during embryonic development and in tumors (7). This is consistent with a role in the development and maintenance of epithelial architecture. CEACAM-5 is upregulated in a wide variety of human tumors and is a commonly used cancer marker (9). It promotes tumor cell migration, invasion, adhesion, and metastasis (10). It also contributes to tumor formation by maintaining cellular proliferation in the presence of differentiation stimuli, and by blocking apoptosis following loss of ECM anchorage (anoikis) (11, 12). The GPI anchoring of CEACAM-5 can be released by GPI-PLD, resulting in a soluble molecule that also promotes tumor metastasis (13). Cell surface expression of CEACAM-5 on tumor cells prevents the adhesion of CEACAM-1 expressing NK cells and provides protection from NK‑mediated lysis (6). CEACAM-5 also binds a subset of Neisseria opacity proteins (Opa) and E. coli adhesion proteins (14‑16). These interactions trigger clustering of the lipid raft-localized CEACAM-5 to sites of pathogen contact (15, 16).
Zebhauser, R. et al. (2005) Genomics 86:566.
Hammarstrom, S. (1999) Semin. Cancer Biol. 9:67.
Schrewe H. et al. (1990) Mol. Cell. Biol. 10:2738.
Hefta, S.A. et al. (1988) Proc. Natl. Acad. Sci. 85:4648.
Garcia, M. et al. (1991) Cancer Res. 51:5679.
Stern, N. et al. (2005) J. Immunol. 174:6692.
Benchimol, S. et al. (1989) Cell 57:327.
Zhou, H. et al. (1993) J. Cell Biol. 122:951.
Goldenberg, D.M. et al. (1976) J. Natl. Cancer Inst. 57:11.
Blumenthal, R.D. et al. (2005) Cancer Res. 65:8809.
Screaton, R.A. et al. (1997) J. Cell Biol. 137:939.
Ordonez, C. et al. (2000) Cancer Res. 60:3419.
Yamamoto, Y. et al. (2005) Biochem. Biophys. Res. Commun. 333:223.
Chen, T. et al. (1997) J. Exp. Med. 185:1557.
Bos, M.P. et al. (1997) Infect. Immun. 65:2353.
Berger, C.N. et al. (2004) Mol. Microbiol. 52:963.
This product is for research use only and is not approved for use in humans or in clinical diagnosis. Primary Antibodies are guaranteed for 1 year from date of receipt.
The concentration calculator allows you to quickly calculate the volume, mass or concentration of your vial. Simply enter your mass, volume, or concentration values for your reagent and the calculator will determine the rest.
Review this Product
Be the first to review our CEACAM5/CD66e Antibody (487609) [Unconjugated] and receive a gift card or discount.
PRODUCT AVAILABILITY: Update Regarding the Evolving COVID-19 Situation
Bio-Techne appreciates the critical role that you and our products and services play in research efforts to further scientific innovation and discovery. We are continually assessing our manufacturing and supplier capabilities during the COVID-19 situation and are implementing precautionary measures to ensure uninterrupted supply of products and services. Currently, and as we abide by local shelter in place orders across the world, we are fully operational and do not anticipate any material supply disruptions across our Bio-Techne brands and product lines. As the situation evolves, our goal is to utilize preventive measures to reduce the threat that COVID-19 poses to our ability to meet the needs of our customers globally.